Across 72 matched Phase III psychiatry trial records from 2024–2026, European activity is concentrated in a small group of country networks: France, Italy, Spain, Germany, Poland, Romania, the Netherlands, Bulgaria, Sweden and Austria. In the fully visible 2024 Phase III cohort alone, 27 records accounted for 195 country-site listings and 6,341 planned participants, with France, Italy, Norway, Poland, Spain and the Netherlands forming the largest participant-allocation signals.
The Phase III psychiatry cohort contains 72 matched records. Activity was highest in 2025 with 36 records, representing 50.0% of the cohort. 2024 contributed 27 records, or 37.5%, while 2026 contributed 9 records, or 12.5%.
The 2025 peak suggests that psychiatry Phase III activity accelerated after the 2024 CTIS transition period, with 2026 still representing a partial-year cohort rather than a mature full-year comparator.
In the 2024 Phase III psychiatry geography records, 6,341 planned participants were distributed across country records. France was the largest allocation signal with 1,453 participants, or 22.9% of the 2024 participant total, followed by Italy with 1,208 participants, or 19.0%, and Norway with 900 participants, or 14.2%.
France and Italy appear as the strongest high-capacity Phase III psychiatry networks in the 2024 cohort. Norway’s 900-participant delirium record shows that a small number of national pragmatic or hospital-based studies can materially shift participant concentration.
Top-site ranking is based on repeated appearances in Phase III psychiatry geography records. The most recurrent site groups include Assistance Publique–Hôpitaux de Paris, Hospital Clinic de Barcelona, Charité Universitätsmedizin Berlin, Centre Hospitalier Henri Laborit, Desbonnet Recherche, University Hospital of Clermont-Ferrand, CHU Montpellier, Oulu Mentalcare, Clinical Research Services Turku and Diagnostics-Consultancy Center Mladost M Varna.
| Rank | Site / Site Group | Country | Observed role |
|---|---|---|---|
| 1 | Assistance Publique–Hôpitaux de Paris | France | Adult, child/adolescent psychiatry, autism, psychosis |
| 2 | Hospital Clinic de Barcelona / Hospital Clinic of Barcelona | Spain | Depression, psychiatry, autism |
| 3 | Charité Universitätsmedizin Berlin | Germany | Psychiatry, neuroscience, paediatric psychiatry |
| 4 | Centre Hospitalier Henri Laborit | France | Psychiatry and medical psychology |
| 5 | Desbonnet Recherche | France | Depression-focused psychiatry studies |
| 6 | University Hospital of Clermont-Ferrand / CHU Gabriel-Montpied | France | Adult psychiatry |
| 7 | Centre Hospitalier Universitaire de Montpellier | France | Adult psychiatry |
| 8 | Oulu Mentalcare Oy | Finland | Depression psychiatry network |
| 9 | Clinical Research Services Turku CRST Oy | Finland | Psychiatry research site |
| 10 | Diagnostics-Consultancy Center Mladost M Varna OOD | Bulgaria | Psychiatry site network |
The strongest recurring sites are not only large university hospitals. Dedicated psychiatry research units and private mental-health research networks appear repeatedly, especially in Bulgaria, Finland, the Netherlands, Poland and Spain.
Depression-related indications dominate the Phase III psychiatry geography cohort. In the 2024 records, depression, major depressive disorder, refractory major depression disorder, treatment-resistant depression and anhedonia-related depression appear repeatedly across France, Italy, Spain, Germany, Sweden, Austria, the Netherlands, Bulgaria, Poland, Finland and Czechia. Other recurring or high-impact areas include schizophrenia, autism spectrum disorder, ADHD, psychotic disorders, delirium, anorexia nervosa, gender dysphoria and substance-use disorders.